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Scd1 Plays a Tumor-Suppressive Role in Survival of Leukemia Stem
Cells and the Development of Chronic Myeloid Leukemia
Haojian Zhang,a Huawei Li,a Ngoc Ho,a Dongguang Li,b and Shaoguang Lia
Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA,a and School of Computer and
Security Science, Edith Cowan University, Mount Lawley, Western Australia, Australiab
Chronic myeloid leukemia (CML) is derived from a stem cell, and it is widely accepted that the existence of leukemia stem cells
(LSCs) is one of the major reasons for the relapse of CML treated with kinase inhibitors. Key to eradicating LSCs is to identify
genes that play a critical role in survival regulation of these stem cells. Using BCR-ABL-induced CMLmouse model, here we
show that expression of the stearoyl-CoA desaturase 1 (Scd1) gene is downregulated in LSCs and that Scd1 plays a tumor-sup-
pressive role in LSCs with no effect on the function of normal hematopoietic stem cells. Deletion of Scd1 causes acceleration of
CML development and conversely overexpression of Scd1 delays CML development. In addition, using genetic approaches, we
show that Pten, p53, and Bcl2 are regulated by Scd1 in LSCs. Furthermore, we find that induction of Scd1 expression by a PPAR
agonist suppresses LSCs and delays CML development. Our results demonstrate a critical role for Scd1 in functional regulation
of LSCs, providing a new anti-LSC strategy through enhancing Scd1 activity.
Leukemia stem cells (LSCs) are defined as transformed hema-topoietic stem cell (HSC) or progenitors that have acquired
unlimited self-renewal ability. It is generally accepted that eradi-
cation of LSCs is required for effectively treating and eventually
curing the diseases. Chronic myeloid leukemia (CML) is believed
to originate from a HSC harboring Philadelphia chromosome
formed through a reciprocal translocation between chromosomes
9 and 22. Human CML is induced by the BCR-ABL oncogene that
produces the chimeric BCR-ABL protein functioning as a consti-
tutively activated tyrosine kinase in leukemogenesis (19, 27, 31).
Although BCR-ABL kinase inhibitors are highly effective in treat-
ing chronic-phase CML patients (5), they do not completely erad-
icate LSCs (5, 7, 10, 12). Therefore, there is an urgent need for
developing anti-LSC strategies, and this approach relies on the
identification of critical target genes in LSCs.
Accumulating evidence shows a close relationship between
cancer and metabolism (15). Cancer cells display changes in fatty
acid metabolism (2), which is associated with modulations of ex-
pression and activity of lipogenic enzymes. One such enzyme is
stearoyl-CoA desaturase (Scd). Scd is an endoplasmic reticulum
enzyme, belonging to a family of 9-fatty acid desaturase iso-
forms. Scd1 catalyzes the biosynthesis of monounsaturated fatty
acids from saturated fatty acids, which are themost abundant fatty
acids present in mammalian organisms (29). Scd1 expression is
detected in almost all tissues, with a predominant expression in
liver, and is involved in regulating metabolic pathways related to
preadipocyte differentiation, insulin sensitivity, metabolism, and
tumorigenesis (6, 8, 13, 28, 29). A recent study indicates that in-
hibition of Scd1 impairs lung cancer cell proliferation, survival,
and invasiveness (8), suggesting that Scd1 plays a supporting role
in lung cancer cells. Another study shows that the level of Scd1
expression correlates with predisposition to liver carcinogenesis
(6). However, the role of Scd1 in leukemogenesis and hematopoi-
esis remains unknown, although it has been suggested that fatty
acid metabolism plays a role in leukemogenesis and hematopoie-
sis (14, 20). In the present study, using the BCR-ABL induced
CMLmousemodel, we found that the expression of the Scd1 gene
was downregulated in LSCs and the deletion of Scd1 accelerated
CML development through affecting the function of LSCs but not
normalHSCs, suggesting that Scd1 plays a tumor-suppressive role
in BCR-ABL leukemogenesis. Our study provides a new strategy
for targeting LSCs by enhancing the Scd1 function.
MATERIALS AND METHODS
Mice. Scd1/, C57BL/6J-CD45.1, andC57BL/6J-CD45.2micewere pur-
chased from the Jackson Laboratory. All mice had a C57BL/6J back-
ground, were bred and maintained in a temperature- and humidity-con-
trolled environment, and given unrestricted access to 6% chow diet and
acidified water.
Generation of retrovirus stocks. The retroviral constructs MSCV-
IRES-GFP, MSCV-BCR-ABL-IRES-GFP, MSCV-BCR-ABL-IRES-Scd1,
and MSCV-Scd1-IRES-humanCD4 MSCV-BCR-ABL-IRES-Pten-IRES-
GFP were used to generate a high-titer, helper-free, replication-defective
ecotropic virus stock by transient transfection of 293T cells as previously
described (16).
Lentiviral transduction and shRNA-mediated knockdown of p53
and Bcl2. Lentiviral short hairpin RNA (shRNA) vector pLKO.1 was pur-
chased from Open Biosystems. The sequences of p53 and Bcl2 shRNA
were as follows: shRNA-p53 sense, 5=-CCAGTCTACTTCCCGCCATAA-
3=; shRNA-p53 antisense, 5=-TTATGGCGGGAAGTAGACTGG-3=;
shRNA-Bcl2 sense, 5=-CGTGATGAAGTACATACATTA-3=; and shRNA-
Bcl2 antisense, 5=-TAATGTATGTACTTCATCACG-3=. For the transduc-
tion of shRNAs, bonemarrow cells fromCMLmice were transfected with
lentiviral shRNA and, 24 h later, were selected under puromycin (2.5
g/ml) for 48 h to enrich shRNA-expressing cells before the next steps.
Bone marrow transduction/transplantation. Eight- to twelve-week-
old C57BL/6 mice were used for bone marrow transduction and trans-
plantation. Retroviral transduction and transplantation of mouse bone
marrow cells for inducing CML and B-cell acute lymphoblastic leukemia
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(B-ALL) by BCR-ABL had been described previously (8, 9, 14, 16, 20, 22).
Briefly, in order to induce CML, donor mice were primed by intravenous
injection with 5-fluorouracil (5-FU; 200 mg/kg) 4 days before collecting
bonemarrow cells. The cells were cultured at 2 107 cells per 10-cmplate
in Dulbecco modified Eagle medium containing 6 ng of recombinant
murine interleukin-3 (IL-3; PeproTech)/ml, 10 ng of recombinant mu-
rine IL-6 (PeproTech)/ml, and 50 to 100 ng of recombinant murine stem
cell factor (SCF; PeproTech)/ml. After prestimulation for 24 h at 37°C, the
cells were transduced with retroviral stocks in the same medium contain-
ing 50% retroviral supernatant, 10 mM HEPES (pH 7.4), and 2 g of
Polybrene/ml. To increase the transduction efficiency, the virus and cells
were cosedimented at 1,000 g for 90 min. A second round of transduc-
tion was performed at 48 h. For inducing B-ALL, bone marrow cells from
non-5-FU-treated donor mice were transduced only once with retroviral
stocks. Recipient mice were prepared by two doses of 550 cGy of gamma
irradiation separated by 3 h, and bonemarrow cells were transplanted into
these recipient mice by intravenous injection. Diseased mice were evalu-
ated by flow cytometric, histopathological, and molecular analyses. For
secondary transplantation, equal numbers of bone marrow cells from
primary CML mice were transplanted into lethally irradiated recipient
mice. For drug treatment, rosiglitazone (GlaxoSmithKline) and imatinib
(Novartis) were given orally in a volume of0.3ml by gavage (100mg/kg,
twice a day for rosiglitazone; 100 mg/kg, twice a day for imatinib) begin-
ning 8 days after bone marrow transplantation (BMT) and continuing
until the morbidity or death of the mice with leukemia.
Flow cytometry analysis.Hematopoietic cells were collected from the
bone marrow and peripheral blood (PB) of CML mice for fluorescence-
activated cell sorting (FACS) analysis. For stem cell analysis, five mice
from each experimental group were sacrificed at day 14 after BMT to
collect bone marrow cells. Red blood cells (RBCs) were depleted using
RBC lysis buffer (containing NH4Cl, KHCO3, and EDTA). To stain the
cells with antibodies, bone marrow cells were suspended in staining me-
dium (Hanks balanced salt solutionwith 2%heat-inactivated calf serum),
followed by incubation with biotin-labeled lineage antibody cocktail con-
taining a mixture of antibodies against CD3, CD4, CD8, B220, Gr-1,
Mac-1, and Ter119 at 4°C for 15 min. After washing, the fluorochrome-
labeled secondary antibody (allophycocyanin-cyanin 7 [APC-Cy7]-con-
jugated streptavidin) for recognizing biotin and phycoerythrin (PE)-con-
jugated c-Kit and APC-conjugated Sca-1 antibodies were added to the
cells for 15 min at 4°C in the dark. Long-term and short-term LSCs were
distinguished by the CD34 antibody. The CML stem cell population
(GFP Lin c-Kit Sca-1) was analyzed by FACS. All of these antibodies
were purchased from eBioscience.
Cell cycle analysis of LSCs was performed by staining cells with
antibodies in combination with Hoechst 33342 for 90 min at 37°C,
followed by flow cytometry analysis. To analyze apoptosis of bone
marrow cells, the cells were stained with annexin V (eBioscience) for
15 min at room temperature. 7-Amino-actinomycin D was added be-
fore flow cytometry analysis.
Leukemia stem cell culture. For mouse leukemia stem cell culture,
bone marrow cells isolated from CML mice were cultured in vitro in the
presence of stemspan SFEM, SCF, insulin-like growth factor 2, thrombo-
poietin, heparin, and anti-fibroblast growth factor as reported previously
for the culture of HSCs. For in vitro treatment, rosiglitazone (Cayman
Chemical) was dissolved in dimethyl sulfoxide (DMSO).
In vitromethylcellulose colony formation assay. LSCs (GFP Lin
Sca-1 c-Kit) from the bonemarrow of CMLmice receiving BCR-ABL-
transduced wild-type (WT) or Scd1/ bone marrow cells were sorted by
FACS and cultured in methylcellulose medium (Methocult GF M3434;
StemCell Technologies) at 37°C in humidified air for 7 days. The colonies
were counted under a microscope.
ChIP of RNA Pol II. Chromatin immunoprecipitation (ChIP) assays
were performed. Briefly, 3  107 leukemia cells from WT and Scd1/
CML mice were incubated with 1% formaldehyde for 10 min at room
temperature before cross-linking was quenched by the addition of 0.125
M glycine. The cells were collected by centrifugation and lysed in lysis
buffer containing 50mMTris-HCl (pH 8.0), 10mMEDTA, 0.5% sodium
dodecyl sulfate, proteinase inhibitors, and phosphatase inhibitors. The
cell suspension was sonicated seven times for 10 s each time with 2-min
intervals on ice using a Misonix Sonicator 3000 at output 8. Sonicated
chromatin was then incubated at 4°C overnight with 5 g of polymer-
ase II (Pol II) antibody (Avalon). Immunoprecipitated DNA was am-
plified by real-time PCR using the following primers: Pten promoter-
sense (5=-CGGGACTCTTTGTGCACTG-3=), Pten promoter-antisense
(5=-GCGGCTCAACTCTCAAACTT-3=), p53 promoter-sense (5=-AACA
GTGGCGGTCCACTTAC-3=), and p53 promoter-antisense (5=-GGGAC
TTGCAGAGTCAGGAT-3=), Bcl2 promoter-sense (5=-CCGGCGGAGA
ATGAAGTAA-3=), and Bcl2 promoter-antisense (5=-CGCACCCTTTCT
CCTCCT-3=).
Real time reverse transcription-PCR (RT-PCR). Total RNA was iso-
lated fromGFP Lin Sca-1 c-Kit bone marrow cells frommice using
an RNeasy minikit (Qiagen, CA). cDNA was synthesized using the Ova-
tion-Pico cDNA synthesis method. All real-time PCRs were done using
the Applied Biosystems 7500. The 25-l reaction systemwas composed of
12.5l of SYBR green, 2.5l of a 20Mprimer mixture, 10 ng of cDNA,
and nuclease-free water. All experiments were performed in triplicate.
-Actin was used as the internal control. The primer sequences were as
follows: Scd1 sense, 5=-TTCTTACACGACCACCACCA-3=; Scd1 anti-
sense, 5=-GCAGGAGGGAACCAGTATGA-3=; Pten sense, 5=-ACACCGC
CAAATTTAACTGC-3=; Pten antisense, 5=-TACACCAGTCCGTCCCTT
TC-3=; p53 sense, 5=-AGAGACCGCCGTACAGAAGA-3=; p53 antisense,
5=-CTGGTAGCATGGGCATCCTTT-3=; Bcl2 sense, 5=-CTGGCTTCTT
CTCCTTCCAG-3=; Bcl2 antisense, 5=-GACGGTAGCGACGAGAGGAA
G-3=; -actin sense, 5=-ATGGAATCCTGTGGCATCCA-3=; and -actin
antisense, 5=-CGCTCAGGAGGAGCAATGAT-3=.
Statistical analysis.Results are given asmeans the standard error of
the mean (SEM). Statistical analysis was performed by using the Student t
test. For survival curves, P values were obtained by using a log-rank test.
RESULTS
Scd1plays a tumor-suppressive role inCMLdevelopment.BCR-
ABL-expressing HSCs (GFP Lin Sca-1 c-Kit cells) in mice
function as LSCs (10). To examine whether BCR-ABL regulates
Scd1 expression in LSCs, using our unique SDL global optimiza-
tion method (17), we reanalyzed the results from our previously
published DNA microarray study (GEO submission GSE10912),
in which we compared the gene expression profiles between LSCs
and normal HSCs.We found that expression of the Scd1 gene was
dramatically lower in BCR-ABL-expressing LSCs compared to
normal HSCs (Fig. 1A), and this downregulation of Scd1 in LSCs
was confirmed by real-time RT-PCR (Fig. 1B). Furthermore, we
analyzed a publicly available gene expression profiling database of
human CML stem cells (25) and found that Scd1 expression was
markedly downregulated in the majority of CML patients in
chronic phase and blast crisis (Fig. 1C). These results suggest that
Scd1 plays a tumor-suppressive role in CML development. To test
this idea, we first investigated whether Scd1 deficiency causes ac-
celeration of CML development using Scd1 homozygous knock-
out (Scd1/) mice. We transduced bone marrow cells from
5-FU-treated wild-type (WT) or Scd1/ mice with the BCR-
ABL-GFP retrovirus, followed by transplanting the transduced
cells into lethally irradiated recipient mice to induce CML. We
found that recipients ofBCR-ABL-transduced Scd1/ bonemar-
row cells developed and died of CML significantly faster than did
recipients of BCR-ABL-transduced WT bone marrow cells (Fig.
1D). The accelerated CML development in the absence of Scd1
correlated with a higher percentage and the total numbers of
GFPGr-1myeloid leukemia cells in PB (Fig. 1E and F) andwith
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FIG 1 Scd1 plays a tumor-suppressive role in CML development. (A) Microarray analysis showed that Scd1 expression was downregulated in BCR-ABL-expressing
LSCs compared to normal stem cells that did not express BCR-ABL. (B) Real-time RT-PCR analysis showed that Scd1 expression was downregulated in LSCs. The
expressiondatawere normalized to-actin expression and are shown asmeans the SEM(n	 3; *,P 0.05). (C) Scd expression in humanCML samples.Microarray
analysis showed expression of Scd1 in CD34 the bone marrow and peripheral blood (PB) cells from 42 chronic-phase (green) and 31 blast-crisis-phase (red) CML
patients compared to normal humanCD34 cells. (D)Kaplan-Meier survival curve for recipients ofBCR-ABL-transducedWTor Scd1/ bonemarrow cells (n	 7 to
8mice per group;P 0.005). (E) Percentages of GFPGr-1 cells in the PB of recipients ofBCR-ABL-transduced bonemarrow cells fromWTor Scd1/ donormice
at day 14 after BMT. (F) Total number of GFP Gr-1 leukemia cells in PB of recipients of BCR-ABL-transduced WT or Scd1/ bone marrow cells. (G) Gross
appearance of lungs and spleens frommice receivingBCR-ABL-transducedWTor Scd1/ bonemarrow cells at day 14 after BMT. (H)Hematoxylin-eosin staining of
tissue sections from the lungs and spleens ofmice receivingBCR-ABL-transducedWTor Scd1/bonemarrowcells at day 14 after BMT(scale bar, 50m). (I) The loss
of Scd1does not affect the homing ability of bonemarrow cells. A total of 6 106 bonemarrow cells fromWTor Scd1/mice (CD45.2)were transplanted into lethally
irradiated recipient mice (CD45.1). The donor-derived bone marrow cells (CD45.2) were detected by FACS in 3 h after BMT. (J) Western blot analysis showed the
expression of Scd1 and BCR-ABL in 293T cells transfected with BCR-ABL-Scd1. (K) Kaplan-Meier survival curve for secondary recipients of equal number of bone
marrowcells fromprimaryCMLmice receivingBCR-ABL-transducedorBCR-ABL-Scd1-transducedWTbonemarrowcells (n	14 to16miceper group;P0.0001).
(L) The percentages of myeloid cells (Gr-1Mac-1) in the PB of secondary recipients of bonemarrow cells from primary CMLmice receiving BCR-ABL-transduced
or BCR-ABL-Scd1-transducedWT bonemarrow cells at days 9, 12, 16, and 28 after BMT.
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more severe splenomegaly and lung hemorrhage (Fig. 1G). Histo-
logical examination showed more extensive infiltration of leuke-
mia cells in the lung and spleen of CMLmice receiving BCR-ABL-
transduced Scd1/ bone marrow cells (Fig. 1H). Because
increased homing of donor bonemarrow cells could lead to accel-
erated CML development, we compared the homing ability of
Scd1/ bone marrow cells to that of WT bone marrow cells 3 h
after the transplantation of the cells into recipientmice.We found
that the percentages of donor-derivedWTand Scd1/ bonemar-
row cells in recipient mice were similar (Fig. 1I), indicating that
Scd1 deficiency does not significantly alter the homing ability of
bone marrow cells. Reversely, we overexpressed Scd1 in donor
bone marrow cells by transducing the cells with retrovirus ex-
pressing bothBCR-ABL and Scd1 (Fig. 1J) to examinewhether the
enforced expression of Scd1 causes a delay of CML development.
We did observe that Scd1 overexpression caused a significant de-
lay of CML development in secondary recipients of bone marrow
cells from the primary CML mice (Fig. 1K). This delayed CML
development correlated with lower percentages ofmyeloid cells in
the PB of the mice (Fig. 1L). Together, these results indicate that
Scd1 plays an inhibitory role in CML development.
We also tested whether Scd1 is required for BCR-ABL induced
B-ALL. We first assessed Scd expression in human B-ALL using a
publicly available microarray data set (GSE5314) of 37 BCR-ABL-
positive (21 of p190BCR-ABL and 16 of p210BCR-ABL) and 17 BCR-
ABL-negative adult ALL (11). We did not observe significant dif-
ference in Scd expression between BCR-ABL-positive ALL and
BCR-ABL-negative ALL and between p190BCR-ABL-positive and
p210BCR-ABL-positive ALL (Fig. 2A). These data suggest that Scd
expression may not be relevant to BCR-ABL in ALL. Consistent
with this idea, recipients of WT or Scd1/ bone marrow cells
transduced with BCR-ABL retrovirus developed and died of ALL
with similar disease latency and survival (Fig. 2B), correlatingwith
similar numbers andpercentages ofGFPB220 leukemia cells in
the PB of the two groups of B-ALL mice (Fig. 2C and D). These
results indicate that Scd1 is dispensable for BCR-ABL induced
B-ALL.
Scd1 suppresses LSCs. The tumor-suppressive effect of Scd1
on CML development could be caused by affecting LSCs. To test
this possibility, we first examined whether deletion of Scd1 causes
an increase of LSCs in bonemarrow of CMLmice. At 2weeks after
CML induction using BCR-ABL-transducedWT or Scd1/ bone
marrow cells, we analyzed bone marrow cells from CML mice by
FACS (Fig. 3A). We found that the percentages and numbers of
total LSCs and long-term (LT) (GFP Lin c-Kit Sca-1
CD34) or short-term (ST) (GFP Lin c-Kit Sca-1 CD34)
LSCs were significantly higher in recipients of BCR-ABL-trans-
duced Scd1/ bonemarrow cells than in recipients of BCR-ABL-
transduced WT bone marrow cells (Fig. 3A). We also cultured
bone marrow cells from CML mice in vitro for 7 days under the
stem cell culture conditions (22) and found that the percentages
and numbers of Scd1/ LSCswere significantly higher than those
of WT LSCs (Fig. 3B).
To investigate whether Scd1 affects self-renewal of LSCs, we
carried out an in vitro serial replating assay to examine the ability
of LSCs to form progenitor colonies. We sorted LSCs from recip-
ients of BCR-ABL-transduced WT or Scd1/ bone marrow cells
and plated the cells in vitro for colony formation. We observed
that Scd1/ LSCs formed significantly higher numbers of colo-
nies compared to WT LSCs (Fig. 3C). To determine whether de-
letion of Scd1 causes an increase in LSC function in vivo, wemixed
BCR-ABL-transducedWT (CD45.1) and Scd1/ (CD45.2) bone
marrow cells in a 1:1 ratio and transplanted into lethally irradiated
mice. At days 8 and 11 after CML induction, FACS analysis
FIG 2 Scd1 does not suppress B-ALL induced by BCR-ABL. (A) Microarray analysis showing Scd expression in human B-ALL samples from 37 BCR-ABL-
positive (21 of p190BCR-ABL and 16 of p210BCR-ABL) and 17 BCR-ABL-negative adult patients. (B) Kaplan-Meier survival curve for recipients receiving BCR-
ABL-transducedWTor Scd1/ bonemarrow cells. Both groups ofmice developed anddied ofALLwith similar disease latency (n	 8mice per group). (C)Total
number of GFPB220 cells in the PB of recipients ofBCR-ABL-transducedWTor Scd1/ bonemarrow cells. (D) FACS analysis revealed no differences in the
percentages of GFP B220 cells in the PB of recipients of BCR-ABL-transduced WT or Scd1/ bone marrow cells.
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showedmuch higher percentages of CD45.2 leukemia cells in PB
compared to the percentages of CD45.1 leukemia cells (Fig. 3D).
To further confirm this result, LSCswere sorted by FACS from the
bone marrow of primary CML mice receiving BCR-ABL-trans-
duced WT (CD45.1) or Scd1/ (CD45.2) bone marrow cells,
mixed in a 1:1 ratio, and then transplanted into secondary recip-
ient mice. Eight weeks later, more than 75% of the GFP Gr-1
leukemia cells in the PB were CD45.2 (Fig. 3E), indicating that
FIG 3 Scd1Suppresses LSCs. (A)Bonemarrowcells fromrecipients ofBCR-ABL-transducedWTorScd1/bonemarrowcellswere analyzedbyFACSat day 14 afterBMT.
The percentages and numbers of total LSCs, LT-LSCs, and ST-LSCs in the bone marrow of recipients of BCR-ABL-transduced Scd1/ donor bone marrow cells were
dramatically higher compared to those in the bone marrow of recipients of BCR-ABL-transducedWT donor bone marrow cells (n	 4 to 7 mice per group). The data are
representative of one of four independent experiments, andmean values ( the SEM) are shown (*, P 0.05). (B) Loss of Scd1 promotes the survival of LSCs in vitro. Bone
marrowcellsfromrecipientsofBCR-ABLtransducedWTorScd1/bonemarrowcellswereculturedfor6daysunderthe invitrostemcellcultureconditions.Thetotalnumbers
andpercentagesofLSCswereanalyzedbyFACS. (C)LossofScd1 increased thecolony-formingabilityofLSCs.ThesortedGFPLinSca-1 c-Kit cells fromCMLmicewere
plated into methylcellulose medium, and the colonies were counted. The cells from colonies were serially replated. The data are representative of one of two independent
experiments.Meanvalues( theSEM)areshown(**,P0.01;***,P0.001). (D)EqualnumbersofBCR-ABL-transducedbonemarrowcells fromWT(CD45.1)orScd1/
(CD45.2)miceweremixedwellandtransplantedintolethally irradiatedWTmice(CD45.2).Atday8and11afterBMT,FACSanalysisgatedinGFPcellpopulationshowedthat
thepercentagesof leukemiacells fromScd1/mice(CD45.2)weredramaticallyhigher than those fromWTmice(CD45.1).Meanvalues (SEM)are shown(**,P0.01; **,
P0.001).(E)AcompetitiverepopulationassayshowedthatthelossofScd1 increasedtheengraftmentofLSCs.Atotalof103sortedLSCsfromthebonemarrowofprimaryCML
mice inducedby transplantingBCR-ABL-transducedScd1/bonemarrowcells (CD45.2)andBCR-ABL-transducedWTbonemarrowcells (CD45.1)weremixedat1:1 ratio,
followedby transplantation into lethally irradiated recipientsmice.Thepercentages ofCD45.2 cells inGFP cell population fromPBwere compared to thoseofCD45.2 cells at
8weeks after BMT(n	 3; ***,P 0.0001).
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Scd1/ LSCs grew predominantly overWT LSCs to induce CML
in recipient mice. Together, these results demonstrate that Scd1
inhibits proliferation of LSCs.
Scd1 deletion inhibits apoptosis but not the cell cycle of
LSCs. To explore cellular mechanisms by which Scd1 regulates LSC
function, we investigated whether Scd1 suppresses LSCs through af-
fecting cell cycle progression or apoptosis. We analyzed LSCs from
the bonemarrow and spleen of CMLmice, and we did not observe a
significant difference in the percentages of LSCs in the S-G2-Mphase
of the cell cycle in thepresenceor absenceofScd1 (Fig. 4A).However,
the percentages of apoptotic LSCs (annexin V) were significantly
lower in the absence than in the presence of Scd1 (Fig. 4B), indicating
Scd1 suppresses LSCs through reducing their survival. To study the
molecular mechanisms by which Scd1 suppresses LSCs and attenu-
ates CML development, we compared the expression of Pten, p53,
and Bcl-2 in WT and Scd1/ leukemia progenitor cells and LSCs.
We found that a Scd1 deficiency caused a decreased expression of
Pten and p53 and an increased expression of Bcl-2 in LSCs (Fig. 4C)
and in GFP Lin leukemia progenitor cells (Fig. 4D). Consistently,
whenweoverexpressedScd1 inLSCs,we foundthatScd1overexpres-
sion induced the expression of Pten and p53 and reduced the expres-
sion ofBcl-2 in LSCs (Fig. 4E). To examine functional significance of
these genes in LSCs,we constructed theBCR-ABL-Pten-GFP retrovi-
ral construct to allow coexpression of BCR-ABL, Pten, and green
fluorescentprotein (GFP) in the samecells (23).We transducedbone
marrow cells obtained from WT or Scd1/ mice with BCR-ABL-
Pten-GFP retrovirus and transplanted into lethally irradiated recipi-
entmice. Recipients of BCR-ABL-transduced Scd1/ bonemarrow
cells displayed higher percentages and numbers of leukemia cells in
the PB compared to recipients of BCR-ABL-transduced WT bone
marrow cells, whereas recipients of BCR-ABL-Pten-transduced WT
and Scd1/ bonemarrow cells showed a lower number of leukemia
cells (Fig. 4F andG).These results indicate thatPten functionsdown-
stream of Scd1 to suppress CML development. To further confirm
the effect of Pten on Scd1/ LSCs, we conducted a colony-forming
assay and found that Pten suppressed the colony formation of
Scd1/ LSCs (Fig. 4H).
To study whether Scd1 functions through Bcl2 and p53, we
knocked down expression of these two genes with lentiviral shRNAs
(Fig. 4I). Because Scd1deficiency caused ahigher level ofBcl2 expres-
sion in Scd1/ LSCs (Fig. 4C), we assumed that Bcl2 knockdown
would reverse thephenotypeofScd1/LSCs.As expected,we found
that Scd1/ LSCs with Bcl2 knockdown gave rise to fewer colonies
compared to control Scd1/ LSCs without Bcl2 knockdown (Fig.
4J), indicating that Bcl2 also mediates the function of Scd1 in LSCs.
Furthermore, we knocked down p53 in Scd1-expressing LSCs and
observed an increased number of colonies (Fig. 4K), although the
increase was not statistically significant, suggesting that p53 plays a
minor role downstream of Scd1 in LSCs.
To examine whether Scd1 regulates expression of Pten, p53,
and Bcl2 at a transcriptional or posttranscriptional level, we first
performed ChIP of RNA Pol II using WT and Scd1/ leukemia
cells and found that the enrichments of Pol II in the promoters of
Pten and p53 were significantly higher in the WT leukemia cells
than in the Scd1/ leukemia cells (Fig. 5A and B). We also found
that the enrichment of Pol II in the promoter of Bcl2 was lower in
the WT leukemia cells than in the Scd1/ leukemia cells (Fig.
5C). These data suggest that Scd1 deletion reduces the transcrip-
tion of Pten and p53 and induces Bcl2 transcription. We tested
whether Scd1 affects mRNA stability of Pten, p53, and Bcl2. Leu-
kemia cells from WT and Scd1/ CML mice were treated with
actinomycinD (5g/ml) to block the transcription, the total RNA
was subsequently harvested at various time points, and themRNA
half-life for Pten, p53, or Bcl2 was examined by RT-PCR. We
found that the mRNA half-lives for Pten and p53 were similar in
WT and Scd1/ leukemia cells, but the mRNA half-life for Bcl2
wasmarkedly increased in Scd1/ leukemia cells (Fig. 5D). These
results indicate that Scd1 regulates the expression of Pten and p53
only at the transcriptional level but regulates the expression of
Bcl2 through affecting both transcription and mRNA stability.
To further study the functional relationship between Scd1 and
Pten/p53, we examined Akt phosphorylation in Scd1/ leukemia
cells, because a published study showed an increased Akt activity in
Scd1/ cells (26). We found that the level of Akt phosphorylation
level was elevated in Scd1/ leukemia cells (Fig. 5E). Therefore, we
sought to determine whether the Akt pathway is involved in the reg-
ulation of Pten and p53 by Scd1.We treated Scd1/CML leukemia
cells with the Akt inhibitor triciribine and found that inhibition of
Akt activity partially reversed expression of Pten but not p53 (Fig. 5F
andG). Inhibition of the PI3K/mTORpathway by the dual inhibitor
PI103 reversed the expression of both Pten and p53 (Fig. 5F and G).
However, inhibition of mitogen-activated protein kinase (MAPK)
activity by the inhibitor SB203580 did not have an effect on the ex-
pression of either Pten or p53 (Fig. 5F and G). These results suggest
that the PI3K/Akt pathway but not theMAPK pathwaymediates the
regulation of Pten and p53 by Scd1.
Induction of Scd1 expression inhibits LSCs and attenuates
CML development. The tumor-suppressive role of Scd1 in CML
development prompted us to test whether the upregulation of
Scd1 expression delays CML development. It has been shown that
the PPAR
 agonists rosiglitazone and pioglitazone induce Scd1
expression, and this Scd1 upregulation is blocked by PPAR
 an-
tagonists in vitro and in vivo (24, 33). Therefore, we treated bone
marrow cells fromCMLmice with rosiglitazone for 7 days in vitro
and found that Scd1 expression was significantly induced in LSCs
(Fig. 6A), accompanied by a dramatic decrease in the numbers of
LSCs (Fig. 6B). To test the effect of rosiglitazone on CML devel-
opment, we treatedCMLwith a placebo, with imatinib alone, with
rosiglitazone alone, and with the two agents in combination. Al-
though treatment with rosiglitazone alone did not prolong the
survival of CMLmice, the combined treatment with rosiglitazone
and imatinib synergized and more significantly prolonged sur-
vival of CML mice than did the use of imatinib alone (Fig. 6C).
This therapeutic effect by rosiglitazone and imatinib correlated
withmuch lower numbers of GFPGr-1myeloid leukemia cells
(Fig. 6D) and increased the apoptosis (Fig. 6E) of leukemia cells in
the PB. Because Scd1 overexpression induced the expression of
Pten and p53 in LSCs (Fig. 4E), we tested whether rosiglitazone
treatment affects Pten and p53 expression. We observed higher
levels of Pten and p53 expression in LSCs after rosiglitazone treat-
ment (Fig. 6F). We also treated the human CML cell line K562
with rosiglitazone for 24 h and found that rosiglitazone treatment
induced the expression of Pten, p53, and Scd1 but decreased the
expression of Bcl2 (Fig. 6G).
To confirm the requirement of Scd1 for the effect of rosiglita-
zone in suppressing leukemia development, we cultured bone
marrow cells from recipients of BCR-ABL transduced WT and
Scd1/ bone marrow cells in vitro under the stem cell culture
conditions in the presence of rosiglitazone.We found that rosigli-
tazone treatment caused a marked decrease (up to 55%) of WT
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LSCs (Fig. 6H). In contrast, rosiglitazone treatment only caused a
modest decrease in the percentage of Scd1/ LSCs (25% de-
crease) (Fig. 6H), indicating that rosiglitazone regulates LSCs
through Scd1. In addition, we compared the impact of rosiglita-
zone on the colony-forming ability between WT and Scd1/
LSCs. Since Scd1/ LSCs had an increased colony-forming abil-
ity (Fig. 3C), we normalized the colony number in the control
group (DMSO) to 100% and showed that the deletion of Scd1
FIG4 Scd1 deletion promotes the survival but not the cell cycle progression of LSCs. (A)Cell cycle analysis showed comparable percentages of cycling LSCs from
the bone marrow and spleens of CML mice receiving BCR-ABL-transduced WT and Scd1/ bone marrow cells. The data shown are from a representative
experiment of three independent experiments, with four to sevenmice per group in each experiment.Mean values ( the SEM) are shown. (B)Apoptotic analysis
of LSCs from the bone marrow and spleens of CML mice receiving BCR-ABL-transduced WT or Scd1/ bone marrow cells. The data shown are from a
representative experiment of three independent experiments, with four to seven mice per group in each experiment. Mean values ( the SEM) are shown (*, P
 0.05; **, P 0.01). (C and D) Real-time RT-PCR analysis of expression of Pten, p53, and Bcl-2 in the sorted WT or Scd1/ LSCs and progenitor cells from
CML mice. Representative data from two independent experiments are shown. Mean values ( the SEM) are shown (*, P 0.05; **, P 0.01). (E) Real-time
RT-PCR analysis demonstrated that Scd1 upregulated the expression of Pten and p53 and downregulated the expression ofBcl-2 in LSCs. Bonemarrow cells from
5-FU-pretreatedmice were cotransduced withMSCV-BCR-ABL-GFP andMSCV-Scd1-hCD4 orMSCV-hCD4. At 14 days after BMT, Scd1-overexpressing LSCs
(hCD4GFP Lin Sca-1 c-Kit) or control LSCs were sorted for extracting total RNA for real-time PCR analysis. Representative data from two independent
experiments are shown. Mean values ( the SEM) are shown (*, P 0.05; **, P 0.01). (F) FACS analysis showing the total numbers of leukemia cells in PB of
recipients of BCR-ABL or BCR-ABL-Pten transduced WT and Scd1/ bone marrow cells at day 14 after BMT. Representative data from two independent
experiments are shown. Mean values ( the SEM) are shown. (G) FACS analysis showing the percentages of leukemia cells in the PB of recipients of BCR-ABL-
transduced orBCR-ABL-Pten-transducedWTand Scd1/ bonemarrow cells at day 14 after BMT. (H)A colony-forming assay showed that Pten overexpression
reduced the colony-forming ability of Scd1/ LSCs. Representative data from two independent experiments are shown. Mean values ( the SEM) are shown
(**,P 0.01; ***,P 0.001). (I)Western blotting of Bcl2 and p53 expression after lentiviral shRNA-mediated knockdown. (J) Colony-forming assay. CMLbone
marrow cells from recipients of BCR-ABL-transducedWT and Scd1/ bone marrow cells were infected with shRNA-Bcl2 or control lentivirus and cultured in
the presence of puromycin for 48 h. Equal numbers of infected cells were plated into methylcellulose medium. Representative data from two independent
experiments are shown. Mean values ( the SEM) are shown (**, P 0.01). (K) Colony-forming assay. CML bone marrow cells from recipients of BCR-ABL-
transduced orBCR-ABL-Scd1-transducedWTbonemarrow cells were infected with shRNA-p53 or control lentivirus and cultured in the presence of puromycin
for 48 h. Equal numbers of infected cells were plated into methylcellulose medium. Representative data from two independent experiments are shown. Mean
values ( the SEM) are shown (**, P 0.01; NS, no significance).
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caused a slight reduction in colony formation after rosiglitazone
treatment (Fig. 6I), further demonstrating that the inhibitory ef-
fect of rosiglitazone on LSCs is mediated through the induction of
Scd1 expression. To examine whether Scd1 plays a similar role in
human leukemia cells, we silenced Scd1 expression in K562 cells
using lentiviral shRNA and found that Scd1 knockdownmarkedly
induced the proliferation of K562 cells and also significantly re-
duced imatinib sensitivity (Fig. 6J), indicating that Scd1 also plays
a tumor-suppressive role in human leukemia cells.
To investigate whether Scd1 synergizes with imatinib in de-
laying CML development, we first analyzed our LSC microar-
ray data and found that imatinib treatment induced Scd1 ex-
pression in LSCs (Fig. 7A). We next treated leukemia cells with
imatinib in vitro under the stem cell culture conditions and
found that treatment with imatinib or rosiglitazone alone
caused an increase in Scd1 expression and that treatment with
both drugs further induced Scd1 expression (Fig. 7B). Further-
more, we treated recipients of BCR-ABL-transduced WT and
Scd1/ bone marrow cells with imatinib and found that, upon
imatinib treatment, the survival of recipients of BCR-ABL-
transduced WT bone marrow cells was significantly longer
than recipients of BCR-ABL-transduced Scd1/ bone marrow
cells (Fig. 7C), a finding consistent with a lower percentage of
leukemia cells in the presence of Scd1 (Fig. 7D).
Scd1 does not affect normal HSCs. Since Scd1 is a suppressor
of LSCs in CML mice (Fig. 3), we wondered whether this inhibi-
tory effect is specific to LSCs with no effect on normal HSCs. We
analyzed non-BCR-ABL-expressing (GFP) HSCs (GFP Lin
c-Kit Sca-1) and LT (GFP Lin c-Kit Sca-1 CD34) and
ST (GFPLin c-Kit Sca-1CD34)HSCs inCMLmice receiv-
ing BCR-ABL-transducedWT or Scd1/ bone marrow cells. We
did not observe any significant differences in the percentages and
numbers of these cell populations between the two groups (Fig.
8A). This result suggests that Scd1 does not suppress normal
HSCs. To confirm this observation, we directly analyzed HSCs
and progenitors in bone marrow of WT and Scd1/ mice. We
found that the percentages of total HSCs (Lin Sca-1 c-Kit),
LT-HSCs (Lin Sca-1 c-Kit CD34 Flk-2), ST-HSCs (Lin
Sca-1 c-Kit CD34 Flk-2), and MPP (Lin Sca-1 c-Kit
CD34 Flk-2) in the bonemarrow of Scd1/mice were similar
FIG 5 Scd1 regulates Pten, p53, and Bcl2 transcription and mRNA stability. (A and B) Pol II ChIP analysis shows the accumulation of Pol II in the promoters of
Pten and p53 of WT cells but not in Scd1/ leukemia cells. (C) Pol II ChIP analysis showed the accumulation of Pol II in the promoter of Bcl2 of Scd1/ cells
but not in WT leukemia cells. (D) Decay time course of the mRNA levels for Pten, p53, and Bcl2 in WT and Scd1/ leukemia cells. (E) Western blot analysis
showed Akt phosphorylation in WT and Scd1/ leukemia progenitor cells. (F) Real-time RT-PCR assay for Pten expression in Scd1/ leukemia cells treated
with PI103, triciribine, and SB203580. Representative data from two independent experiments are shown. Mean values ( the SEM) are shown (*, P 0.05; **,
P 0.01). (G) Real-time RT-PCR assay for p53 expression in Scd1/ leukemia cells treated with PI103, triciribine, and SB203580. Representative data from two
independent experiments are shown. Mean values ( the SEM) are shown (*, P 0.05; **, P 0.01).
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to those in WT mice (Fig. 8B). Although the percentage of GMP
(Lin Sca-1 c-Kit CD34 FcyRII/IIIhi) was modestly higher in
Scd1/ mice than in WT mice, the percentages of CMP (Lin
Sca-1 c-KitCD34 FcyRII/IIIlo) andMEP (Lin Sca-1 c-Kit
CD34 FcyRII/IIIlo) in bone marrow were similar between
Scd1/ and WT mice (Fig. 8B). In addition, Scd1/mice had a
normal distribution of mature myeloid cells (Gr-1Mac-1) and
B lymphoid cells (B220) (Fig. 8C).
To determine whether Scd1 affects the self-renewal capacity of
HSCs, we performed a competitive repopulation assay. Bonemar-
row cells (2 105) fromWT (CD45.2) or Scd1/ (CD45.2) mice
were transplanted into each lethally irradiated CD45.1 mouse,
along with equal numbers of WT CD45.1 competitor bone mar-
row cells. Analysis of these chimeric mice was performed by FACS
over 1 to 4 months after the BMT. We found that the percentages
of WT and Scd1/ donor-derived myeloid cells (Gr-1, Mac-
FIG 6 Induction of Scd1 expression suppresses LSCs and attenuates CML development. (A) Real-time RT-PCR showed the induction of Scd1 expression by
rosiglitazone in LSCs. Bonemarrow cells from primary CMLmice were treated with rosiglitazone in vitro for 7 days, the LSCs were sorted by FACS, and the total
RNAwas isolated for RT-PCR analysis. Representative data from two independent experiments are shown.Mean values ( the SEM) are shown (***,P 0.001).
(B) Bone marrow cells from primary CML mice were treated with rosiglitazone in vitro for 7 days, and the number of LSCs was decreased upon rosiglitazone
treatment. (C) Kaplan-Meier survival curve for CML mice treated with a placebo, with rosiglitazone alone, with imatinib alone, or with both rosiglitazone and
imatinib (n	 6 to 12mice per group; P	 0.009). (D) The total numbers of leukemia cells in the PB of CMLmice treatedwith a placebo, with rosiglitazone alone,
with imatinib alone, or with both rosiglitazone and imatinib were analyzed at days 4, 8, 14, 21, 28, and 35 after initiation of the treatments. The results are
representative of two independent experiments. (E) FACS analysis of the percentages of apoptotic leukemia cells in PB of CMLmice treated with imatinib alone
(n	 5) or with both rosiglitazone and imatinib (n	 5) for 8 weeks. Mean values ( the SEM) are shown (*, P 0.05). (F) Rosiglitazone treatment induced the
expression of Pten and p53 in LSCs in vitro. Mean values ( the SEM) are shown (**, P 0.01; ***, P 0.001). (G)Western blot analysis showed the regulation
of expression of Pten, p53, Bcl2, and Scd1 by rosiglitazone in human K562 cells. (H) Percentages of WT and Scd1/ LSCs cultured in vitro in the presence of
rosiglitazone. (I) Scd1 deletion reduced the inhibitory effect of rosiglitazone on colony formation of LSCs. Bone marrow cells from recipients of BCR-ABL-
transducedWT and Scd1/ bonemarrow cells were plated in methylcellulose medium in the presence of rosiglitazone. Note that the CFU for cells treated with
DMSOwas defined as 100%. (J) Scd1 knockdown induced the proliferation of human K562 leukemia cells. The inset panel shows the decreased Scd1 expression
mediated by lentiviral shRNA. Mean values ( the SEM) are shown (*, P 0.05).
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1), B cells (B220), and T cells (CD3e) in PB were similar at 4
and 8 weeks after BMT; however, the percentages of Scd1/ do-
nor-derived myeloid cells at 12 and 16 weeks and the percentages
of Scd1/ donor-derived B and T cells at 16 weeks were slightly
higher than those of WT donor-derived cells (Fig. 8D), although
the difference was not statistically significant. At 16 weeks, we
directly compared the percentages of donor-derived WT and
Scd1/ HSCs in bone marrow, and we did not observe a signifi-
cant difference (Fig. 8E). Together, these results indicate that Scd1
does not affect the function of normal HSCs.
DISCUSSION
Our study supports a critical role for Scd1 in CML development
through specifically regulating LSCs but not normal HSCs. In our
previously published study, we identified another lipid-metabolic
gene, arachidonate 5-lipoxygenase (Alox5), required for func-
tional regulation of LSCs but not normal HSCs (1). Our identifi-
cation of Scd1 in the present study strengthens the feasibility of
specifically targeting LSCs in the treatment of CML.
Althoughdysregulated expression of Scd1 has been observed in
several human cancers (32), to our knowledge the present study
provides the first evidence for the role of Scd1 in hematopoiesis
and leukemogenesis. Previous data indicated that Scd1 regulated
cancer cell proliferation and survival. Knockdownof Scd1 by small
interfering RNA significantly reduced the survival of multiple hu-
man tumor cell lines (21). In contrast, in the present study, we
found that Scd1 plays a tumor-suppressive role in LSCs through
regulating apoptosis of LSCs. This indicates that Scd1 plays differ-
ent roles in different cancers. In addition, while CML develop-
ment was accelerated in the loss of Scd1, the development of Ph
B-ALL could be unimpaired. It is known that CML is a stem cell
disease, while the cell of origin for ALL is a committed B-cell
progenitor (16). Therefore, the distinct roles of Scd1 in different
leukemia subtypes suggest that Scd1 acts in a cell-type-specific
manner.
With respect to the molecular basis for the functional regula-
tion of LSCs by Scd1, we show that Scd1 deficiency results in dys-
regulated expression of apoptosis-related genes, including de-
creased expression of Pten and p53 and increased expression of
Bcl-2, which is consistent with the observation from other groups
showing that Scd1 deficiency reduces cardiac apoptosis in ob/ob
mice due to the increased expression of antiapoptotic factor Bcl-2
(4). In addition, we also show that treatment with PPAR
 agonist
induces the apoptosis of leukemia cells, which is associated with a
higher expression of Scd1, Pten, and p53. A recent study showed
that unsaturated fatty acid affected Pten expression in hepatoma
FIG 7 Scd1 mediates the inhibitory effect of imatinib on CML development. (A) Microarray analysis showed that imatinib treatment induced Scd1 expression
in LSCs. (B) Real-time RT-PCR showed that imatinib treatment induced Scd1 expression in leukemia cells (*, P 0.05; **, P 0.01). (C) Kaplan-Meier survival
curve for imatinib treated recipients of BCR-ABL-transduced WT and Scd1/ bone marrow cells (n	 5 to 8 mice per group; P	 0.002). (D) FACS analysis
showed the percentages of leukemia cells in PB of recipients of BCR-ABL-transduced WT and Scd1/ bone marrow cells at days 4, 7, and 20 after imatinib
treatment.
SCD1 in Survival Regulation of Leukemia Stem Cells
May 2012 Volume 32 Number 10 mcb.asm.org 1785
FIG 8 Scd1 deficiency does not affect the function of normal HSCs. (A) The total numbers and percentages of HSCs (GFP Lin c-Kit Sca-1), LT-HSCs
(GFP Lin c-Kit Sca-1 CD34), and ST-HSCs (GFP Lin c-Kit Sca-1 CD34) in the GFP cell population of recipients of BCR-ABL-transducedWT
and Scd1/ bone marrow cells were compared (NS, no significance). (B) The percentages of normal stem cells and progenitors from WT and Scd1/ bone
marrow (n	 4) were compared. HSC, Lin c-Kit Sca-1; LT-HSC, Lin c-Kit Sca-1 CD34 Flk-2; ST-HSC, Lin c-Kit Sca-1 CD34 Flk-2; MPP,
Lin c-Kit Sca-1 CD34 Flk-2; progenitor, Lin c-Kit Sca-1; CMP, Lin c-Kit Sca-1 CD34 Fc
RII/IIIlo; GMP, Lin c-Kit Sca-1 CD34
Fc
RII/IIIhi; MEP, Lin c-Kit Sca-1 CD34 Fc
RII/IIIlo. (C) The percentages of myeloid cells (Gr-1) and B cells (B220) in the bone marrow of WT and
Scd1/mice were compared. Mean values ( the SEM) are shown. (D) Competitive repopulation assay for the effect of Scd1 on normal HSCs. FACS analysis
of the percentages of donor-derived (CD45.2) myeloid cells (Gr-1, Mac-1), B cells (B220), and T cells (CD3e) in the PB of recipients of normal bone
marrow cells fromWT and Scd1/mice was performed. (E) FACS analysis of the donor-derived (CD45.2) HSCs in the bonemarrow of recipients ofWT and
Scd1/mice (n	 8 mice per group). Mean values ( the SEM) are shown.
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cells through regulating microRNA-mediated Pten mRNA stabil-
ity, which depends on the mTOR and NF-B pathways (30). Our
results show that Scd1 regulates Pten, p53, and Bcl2 at the tran-
scriptional and/or posttranscriptional level. However, detailed
mechanisms by which Scd1 regulates expression of Pten, p53, and
Bcl2 need to be further investigated in the future.
The mechanisms by which a PPAR
 agonist inhibits LSCs is
unclear. PPARs are ligand-binding transcription factors belong-
ing to the nuclear receptor family. PPARs are involved in regulat-
ing lipid metabolism, cell growth, and survival. It has been shown
that activation of the PPAR pathway with the dual PPAR and
PPAR
 ligand TZD18 induces apoptosis and inhibits the prolifer-
ation of human CML cells (18, 34). Although rosiglitazone syner-
gized with imatinib to delay CML development, rosiglitazone
alone failed to do so. One possibility is that rosiglitazone alone is
not effective enough to prevent lung hemorrhage, amajor cause of
death of CML mice. Another possibility is that the level of Scd1
induced by rosiglitazone is not high enough to delay CML devel-
opment. PPAR agonists are anti-inflammatory agents since they
inhibit the expression of several proinflammatory cytokines and
most chemokines (3). A role of an anti-inflammatory agent on
LSCs is supported by our previous study showing that the anti-
inflammatory drug Zileuton, which inhibits the function of the
Alox5 gene, prolongs the survival of CML mice (1). We treated
LSCs from CML mice in vitro with rosiglitazone alone or both
rosiglitazone andZileuton and found that the dual drug treatment
resulted in a significantly lower percentage of LSCs compared to
treatment with rosiglitazone alone (data not shown), indicating
that an Alox5 inhibitor synergizes with PPAR agonist to inhibit
LSCs. Together, enhancement of Scd1 activity provides an attrac-
tive strategy for eliminating LSCs in CML.
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